brontictuzumab
Phase 1Monoclonal antibody
brontictuzumab is one of 63 small molecule programs targeting Adenoid Cystic Carcinoma. It is currently in Phase 1.
2
Indications
2
Total Trials
0
Active Trials
62
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Sutent
PfizerPhase 3
Lynparza
AstraZenecaPhase 3
Lumakras
AmgenPhase 3
Folinic Acid
RochePhase 3
Trifluridine/tipiracil
AbbViePhase 3
Ofev
Boehringer IngelheimPhase 3
Donafenib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
Levo-Leucovorin
PfizerPhase 3
Oxaliplatin, /m2
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for brontictuzumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 1[1]
- Company
- OOncoMed Pharmaceuticals, Inc.